Pediatrix Medical Group, Inc. (MD)
Healthcare
- Fundamental
- 4
- Sentiment
- 2
- Technical
- 4
Do Nothing: input price 26.5 is above the $25 ceiling and qualitativeScore 2 is below the required floor of 3.
Company overview
Pediatrix Medical Group, Inc. provides specialized medical services for newborns, expectant mothers, and pediatric patients in the U.S. and Puerto Rico. The company focuses on neonatal care, maternal-fetal medicine, and pediatric cardiology, among other subspecialties. Established in 1979 and formerly known as MEDNAX, Inc., Pediatrix manages a network of approximately 2,700 physicians.
Fundamental
goodPediatrix exhibits strong profitability and cash flow with manageable leverage, but faces growth and execution risks.
Pediatrix shows a strong rebound in profitability and free cash flow with manageable leverage and no SEC-filed going-concern or covenant red flags. Valuation looks reasonable (low-teens earnings multiple and about a 10% free-cash-flow yield), but multi-year top-line growth has been modest and reimbursement/regulatory exposure plus revenue-cycle execution remain the key risks to monitor.
Sentiment
weakMarket sentiment is cautious due to margin compression and growth softness despite EBITDA strength.
Near-term narrative is dominated by the company’s announced Aug-04 Q2 earnings update: headline beat/reaffirmed EBITDA themes were overshadowed by margin/same-store concerns and a sharp post-earnings selloff in several write-ups. Media sentiment is mildly positive but essentially flat versus the 30–90d baseline (polarity_score ~+0.11 vs ~+0.13), with little retail discussion and no regulator-confirmed legal overhang surfaced (court-record scan was partially blocked).
Technical
goodThe stock is above key moving averages with strong ADX, but momentum has cooled slightly.
Chart quality is strong: price is stacked above the 20/50/200-day averages and EMA9/21, while ADX remains high. I stop short of a 5 because MACD is still below its signal after the earnings-driven volatility burst, so momentum has not fully re-accelerated.
You’re looking at 2026-08-13 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.